🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating globally, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Secure Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

Based on results detailed in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The trial enrolled nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to license and sell the drug in numerous regions with limited resources.

Medical professionals on the front lines have voiced optimism. Having a easy-to-administer therapy such as this is seen as a "revolutionary step" for public health efforts. This is viewed as essential to reduce the burden of the illness for patients and to halt the transmission of untreatable gonorrhoea worldwide.